# Grok-4.1-Fast Review

**Role:** External referee review
**Model:** x-ai/grok-4.1-fast
**Paper:** paper.pdf
**Timestamp:** 2026-02-26T18:28:11.268722
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18663 in / 2863 out
**Response SHA256:** a9b3847521a0cc08

---

### 1. IDENTIFICATION AND EMPIRICAL DESIGN (CRITICAL)

The identification strategy is credible and innovative for a continuous-treatment DiD claiming UK-specific housing price effects from Brexit via pre-existing networks. The baseline (Eq. 1: Exposure_d × Post_t + dept FE + quarter FE) relies on parallel trends in log median prices, tested via event studies (Fig. 1: borderline pre-trend F-tests, p=0.038 SCI/0.048 stock) and gap event studies for triple-diff (Fig. 3: p=0.240 stock, reassuring). Key assumptions explicit: parallel trends (testable), no anticipation (census ref. Jan 1 2016), SUTVA/no spillovers (LOO/ conservative bias claim), exclusion (UK shock doesn't hit controls). Threats well-discussed (cosmopolitan confounding, reverse causality, compositional shifts) and addressed via pre-determined census stock (validates SCI, Table 1 col 2), residualized SCI (orthogonal to confounders, Table 1 col 3), and triple-diff (Eq. 2: identifies from within-dept/quarter house-apartment gaps post-pre, absorbs all dept-time shocks).

Triple-diff is the strongest element: house-apartment asymmetry leverages stylized fact (UK buyers favor houses; Sec. 2.3), with German placebo null (Table 2 col 4, p=0.66). Multi-country placebos (Table 5) and horse-race (UK survives, placebos insignificant) bolster. Timing coherent: post=2016Q3 (immediate GBP drop), data 2014-2023 covers pre/post without gaps (some cells sparse, but N=3510 dept-qtr coherent). Commune-level triple (Table 7, ~200k obs) sharpens power while clustering at 96 depts.

Issues: (i) Pre-2020 triple null (Table 3: p=0.93 SCI/0.98 stock), full-sample driven by COVID rural boom (acknowledged Sec. 8.4); short-window DiD survives (Table 6 col 4) but triple needs pre-2020 emphasis. (ii) Placebo resolution mismatch (GADM2 UK/DE vs. GADM1 others; Sec. 8.1) risks apples-oranges (coarse GADM1 may bias via regional composition). (iii) Dept trends kill DiD stock (Table 1 col 6; expected but flags low-freq ID). Overall, design shifts credible weight to triple/horse-race, rejecting naive TW DiD pitfalls (no already-treated).

### 2. INFERENCE AND STATISTICAL VALIDITY (CRITICAL)

Valid and thorough. All main estimates report dept-clustered SEs (96 clusters >50 threshold; MacKinnon 2023 cited), p-values; samples coherent (e.g., 3510→3209 stock due to 89 depts; 7010 triple after singletons dropped). CIs in figures (e.g., Figs. 1-4) but absent tables (flag: text claims match reported SEs, e.g., Table 1 stock p=0.001). Bootstrap (pairs, 499 reps; Table 4) validates cluster-robust (e.g., triple SCI p=0.106→0.054 bootstrap, less conservative). Wild bootstrap (commune), permutation RI (Fig. 6), HonestDiD (Fig. 5: robust to moderate pre-trend nonlinearity). No RDD/TWFE-staggered issues (uniform timing). Power acknowledged (triple imprecise at dept, fixed at commune). Passes.

### 3. ROBUSTNESS AND ALTERNATIVE EXPLANATIONS

Comprehensive. Core robust to: samples (no IdF/Corsica/2014-18; Table 6), binary exposure (col 5), LOO (Fig. 7 no outliers), 2-way cluster. Placebos meaningful (German null triple; multi-country horse-race clean; residualized insig flags 20% cosmopolitan share). Falsification: pre-trend tests, exchange (Table 8 sig but placebo too → macro confound). Mechanisms reduced-form (exchange/geographic het; Tables 8-9): no overclaim to structural. COVID limitation clear (pre-2020 null triple), external validity bounded (French houses, no buyer IDs). Distinguishes: DiD picks trends + shock; triple isolates UK-specific.

Weaknesses: Individual GADM1 placebos sig triple (BE/IT/ES p<0.05 Table 5; possible composition/measurement); trends attenuate DiD; no direct UK buyer data.

### 4. CONTRIBUTION AND LITERATURE POSITIONING

Clear differentiation: Methodological advance on SCI/shift-share (Bailey 2018/21, Borusyak 2022, Adao 2019; naive fails here, toolkit fixes). Substantive: First cross-border Brexit housing (vs. trade Born 2019, uncertainty Hassan 2024; closest Mastrosavvas 2024 UK-internal). Foreign demand (Saiz 2010 etc.). Coverage sufficient; add: Dube/Owens (2024 AER) on SCI granularity/confounding (why GADM mismatch matters); Sun/Shah (2021) TW weights (noted but quantify?).

### 5. RESULTS INTERPRETATION AND CLAIM CALIBRATION

Well-matched: Census DiD strong (1pp per log UK stock; Table 1 col 2), triple suggestive (stock 0.0029 p=0.58 dept →0.0078* commune; SCI 0.0285 p=0.106→0.0156 commune), horse-race UK+ while placebos- (Table 5). No contradictions (e.g., residual insig →confounding; trends kill →low-freq ID). Policy mild ("template for SCI"). No overclaim (Sec. 8.4: "stronger for post-2016 diff than referendum causality"; COVID ambiguous). Figures support claims (e.g., Fig. 3 validates triple pre-trends; no table-figure mismatch).

### 6. ACTIONABLE REVISION REQUESTS

**1. Must-fix issues before acceptance**
- Harmonize placebo resolutions: Re-estimate BE/NL/IT/ES at GADM2 (if data allow) or drop GADM1; report why unavailable. *Why:* Mismatch undermines horse-race (Sec. 8.1 admits); apples-oranges biases triple falsification. *Fix:* New Table 5 panel; if infeasible, clarify SCI availability (Bailey data?).
- Clarify/report COVID timing: Add pre-2020 triple event study (extend Fig. 2/4); decompose full-sample effect (2016-19 vs. 2020-23 shares). *Why:* Null pre-2020 triple (Table 3) vs. sig full (Table 2) risks misattr. to Brexit vs. pandemic; short DiD ok but triple centerpiece. *Fix:* New fig/table; bound "post-2016 regime" claim.

**2. High-value improvements**
- Report CIs/pvals consistently in all tables (e.g., Table 2 beside coeffs). *Why:* Top journals require (AER style); aids uncertainty calibration. *Fix:* Add cols; stars ok but CIs essential.
- Quantify TWFE weights/Sun-Shah bias in DiD event studies. *Why:* Continuous treatment + dynamics risk neg. weights (noted Sec. 3.5). *Fix:* Appendix table (min/max weights per period).
- Buyer comp: Regress property fixed effects (age/size from DVF?) × Post × Exposure. *Why:* Addresses compositional threat (Sec. 3.5). *Fix:* New robustness table.

**3. Optional polish**
- Add Dube/Owens (2024) on SCI pitfalls. *Why:* Directly relevant to cosmopolitan confounder.
- Exchange mechanism: Interact sterling weakness separately pre/post-2020. *Why:* GBP path differed.

### 7. OVERALL ASSESSMENT

**Key strengths:** Elegant triple-diff (absorbs all dept shocks, clean German placebo); thorough inference (bootstrap/RI/HonestDiD); honest limitations (COVID, precision, placebos); methodological template for SCI designs. Replication-ready (GitHub).

**Critical weaknesses:** Pre-2020 triple null questions Brexit timing; GADM mismatch weakens multi-placebo; DiD fragile to trends (expected but caps causal claim).

**Publishability after revision:** High – sound core, fixes contained (COVID/placebo) yield top-journal ready.

DECISION: MINOR REVISION